1257214-59-7

Basic information

• Product Name: N-{1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarbonyl}-methanesulfonamide
• Synonyms: N-{1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarbonyl}-methanesulfonamide
• CAS NO: 1257214-59-7
• Molecular Weight: 365.258
• Mol File: 1257214-59-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: N-{1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarbonyl}-methanesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-{1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarbonyl}-methanesulfonamide(1257214-59-7)
• EPA Substance Registry System: N-{1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarbonyl}-methanesulfonamide(1257214-59-7)

Safety Data

• Hazardous Substances Data: 1257214-59-7(Hazardous Substances Data)

Upstream product

• 345965-52-8 1-(4-bromophenyl)cyclopropanecarboxylic acid 
• 124276-67-1 1-(4-bromophenyl)cyclopropanecarbonitrile 
• 16532-79-9 4-Bromophenylacetonitrile 
• 1257214-56-4 N-[1-(4-bromo-phenyl)-cyclopropanecarbonyl]-methanesulfonamide 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1284212-22-1 N-[1-(4'-{4-[(5-Benzyl-[1,3,4]oxadiazol-2-yl)-hydroxy-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarbonyl]-methanesulfonamide 
• 1396007-78-5 {5-[4'-(1-methanesulfonylaminocarbonyl-cyclopropyl)biphenyl-4-yl]-3-methyl-3H-[1,2,3]triazol-4-yl}carbamic acid (R)-1-phenyl-ethyl ester 
• 1396007-80-9 {5-[4'-(1-methanesulfonylaminocarbonyl-cyclopropyl)biphenyl-4-yl]-3-methyl-3H-[1,2,3]triazol-4-yl}carbamic acid (R)-1-(3-trifluoromethylphenyl)ethyl ester 

Relevant articles and documents

N-ALKYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful

Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts

Lysophosphatidic acid is a class of bioactive phospholipid that mediates most of its biological effects through LPA receptors, of which six isoforms have been identified. The recent results from LPA1 knockout mice suggested that blocking LPA1 signaling could provide a potential novel approach for the treatment of idiopathic pulmonary fibrosis. Here, we report the design and synthesis of pyrazole- and triazole-derived carbamates as LPA1-selective and LPA1/3 dual antagonists. In particular, compound 2, the most selective LPA1 antagonist reported, inhibited proliferation and contraction of normal human lung fibroblasts (NHLF) following LPA stimulation. Oral dosing of compound 2 to mice resulted in a dose-dependent reduction of plasma histamine levels in a murine LPA challenge model. Furthermore, we applied our novel antagonists as chemistry probes and investigated the contribution of LPA1/2/3 in mediating the pro-fibrotic responses. Our results suggest LPA1 as the major receptor subtype mediating LPA-induced proliferation and contraction of NHLF.

POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.